Seven Indian Pharma Companies In Fray To Develop COVID-19 Vaccine
New Delhi: Among the legion efforts being made all over the world to develop a vaccine to contain the spread of coronavirus, are seven Indian pharma companies.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec NSE 5.28 %, Indian Immunologicals, Mynvax, and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India, reported The Economic Times (ET).
Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within months because of the pandemic.
Having received approval to conduct phase I and II clinical trials for its vaccine candidate Covaxin, developed and manufactured in Hyderabad, it started human clinical trials last week at Rohtak’s Post-Graduate Institute of Medical Sciences.
Serum Institute of India
It AstraZeneca Oxford vaccine is undergoing phase III clinical trials. It will also start human trials in India in August 2020, ET reported. They hope to make the vaccine available by the end of this year.
It is looking to complete clinical trials of its COVID-19 vaccine candidate ZyCoV-D in seven months. It started clinical trials last week with the first human dosing.
It setting up a joint venture firm in Ireland with US-based Refana Inc to develop a vaccine for COVID-19. The company aims to manufacture over 500 million doses of their COVID-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year, reported ET quoting the company.
This subsidiary of National Dairy Development Board (NDDB), has an agreement with Australia’s Griffith University to develop a vaccine.
Others in the fray are:
Mynvax and Biological E